These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 11243402)

  • 41. Pharmacodynamic and DNA methylation studies of high-dose 1-beta-D-arabinofuranosyl cytosine before and after in vivo 5-azacytidine treatment in pediatric patients with refractory acute lymphocytic leukemia.
    Avramis VI; Mecum RA; Nyce J; Steele DA; Holcenberg JS
    Cancer Chemother Pharmacol; 1989; 24(4):203-10. PubMed ID: 2473850
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Close correlation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate, an intracellular active metabolite, to the therapeutic efficacy of N(4)-behenoyl-1-beta-D-arabinofuranosylcytosine therapy for acute myelogenous leukemia.
    Yamauchi T; Kawai Y; Goto N; Kishi S; Imamura S; Yoshida A; Urasaki Y; Fukushima T; Iwasaki H; Tsutani H; Masada M; Ueda T
    Jpn J Cancer Res; 2001 Sep; 92(9):975-82. PubMed ID: 11572766
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A novel bioluminescent bacterial biosensor for measurement of Ara-CTP and cytarabine potentiation by fludarabine in seven leukaemic cell lines.
    Anderson E; Smith MA; Martin A; Ruddock M; Lamont J; Alloush H; Conway M; Mehta P; Smith JG; Salisbury V
    Leuk Res; 2013 Jun; 37(6):690-6. PubMed ID: 23473919
    [TBL] [Abstract][Full Text] [Related]  

  • 44. 1-beta-D-arabinofuranosylcytosine metabolism and incorporation into DNA as determinants of in vivo murine tumor cell response.
    Riva CM; Rustum YM
    Cancer Res; 1985 Dec; 45(12 Pt 1):6244-9. PubMed ID: 2998596
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Augmentation of 1-beta-D-arabinofuranosylcytosine (Ara-C) cytotoxicity in leukaemia cells by co-administration with antisignalling drugs.
    Freund A; Boos J; Harkin S; Schultze-Mosgau M; Veerman G; Peters GJ; Gescher A
    Eur J Cancer; 1998 May; 34(6):895-901. PubMed ID: 9797704
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Granulocyte-macrophage colony-stimulating factor and interleukin-3 enhance the incorporation of cytosine arabinoside into the DNA of leukemic blasts and the cytotoxic effect on clonogenic cells from patients with acute myeloid leukemia.
    Hiddemann W; Kiehl M; Zühlsdorf M; Busemann C; Schleyer E; Wörmann B; Büchner T
    Semin Oncol; 1992 Apr; 19(2 Suppl 4):31-7. PubMed ID: 1553573
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effects of fludarabine and gemcitabine on human acute myeloid leukemia cell line HL 60: direct comparison of cytotoxicity and cellular Ara-C uptake enhancement.
    Santini V; D'Ippolito G; Bernabei PA; Zoccolante A; Ermini A; Rossi-Ferrini P
    Leuk Res; 1996 Jan; 20(1):37-45. PubMed ID: 8632676
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Quantitation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in the leukemic cells from bone marrow and peripheral blood of patients receiving 1-beta-D-arabinofuranosylcytosine therapy.
    Plunkett W; Hug V; Keating MJ; Chubb S
    Cancer Res; 1980 Mar; 40(3):588-91. PubMed ID: 6937239
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Modulation of arabinosylcytosine metabolism by arabinosyl-2-fluoroadenine in lymphocytes from patients with chronic lymphocytic leukemia: implications for combination therapy.
    Gandhi V; Nowak B; Keating MJ; Plunkett W
    Blood; 1989 Nov; 74(6):2070-5. PubMed ID: 2478221
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Accumulation of arabinosyluracil 5'-triphosphate during arabinosylcytosine therapy in circulating blasts of patients with acute myelogenous leukemia.
    Gandhi V; Xu YZ; Estey E
    Clin Cancer Res; 1998 Jul; 4(7):1719-26. PubMed ID: 9676847
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Biochemical modulation of Ara-C effects by amidox, an inhibitor of ribonucleotide reductase in HL-60 promyelocytic human leukemia cells.
    Höchtl T; Horvath Z; Bauer W; Karl D; Saiko P; Elford HL; Fritzer-Szekeres M; Szekeres T
    Life Sci; 2004 Jan; 74(9):1071-80. PubMed ID: 14687648
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Metabolic basis of arabinonucleoside selectivity for human leukemic T- and B-lymphoblasts.
    Verhoef V; Fridland A
    Cancer Res; 1985 Aug; 45(8):3646-50. PubMed ID: 2410098
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Monitoring of intracellular 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in 1-beta-D-arabinofuranosylcytosine therapy at low and conventional doses.
    Yamauchi T; Kawai Y; Kishi S; Goto N; Urasaki Y; Imamura S; Fukushima T; Yoshida A; Iwasaki H; Tsutani H; Masada M; Ueda T
    Jpn J Cancer Res; 2001 May; 92(5):546-53. PubMed ID: 11376564
    [TBL] [Abstract][Full Text] [Related]  

  • 54. On the interaction between cytosine arabinoside and etoposide in vivo and in vitro.
    Liliemark J; Knochenhauer E; Gruber A; Pettersson B; Björkholm M; Peterson C
    Eur J Haematol; 1993 Jan; 50(1):22-5. PubMed ID: 8436210
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Intracellular pharmacodynamic studies of the synergistic combination of 6-mercaptopurine and cytosine arabinoside in human leukemia cell lines.
    Ramilo-Torno LV; Avramis VI
    Cancer Chemother Pharmacol; 1995; 35(3):191-9. PubMed ID: 7805176
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cellular pharmacology of N4-hexadecyl-1-beta-D-arabinofuranosylcytosine in the human leukemic cell lines K-562 and U-937.
    Horber DH; Schott H; Schwendener RA
    Cancer Chemother Pharmacol; 1995; 36(6):483-92. PubMed ID: 7554040
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effects of bryostatin 1 and rGM-CSF on the metabolism of 1-beta-D-arabinofuranosylcytosine in human leukaemic myeloblasts.
    Grant S; Jarvis WD; Turner AJ; Wallace HJ; Pettit GR
    Br J Haematol; 1992 Nov; 82(3):522-8. PubMed ID: 1486032
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Modulation of 1-[beta-D-arabinofuranosyl] cytosine-induced apoptosis in human myeloid leukemia cells by staurosporine and other pharmacological inhibitors of protein kinase C.
    Grant S; Turner AJ; Bartimole TM; Nelms PA; Joe VC; Jarvis WD
    Oncol Res; 1994; 6(2):87-99. PubMed ID: 7949469
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Mechanism of synergistic cell killing by hydroxyurea and cytosine arabinoside.
    Tanaka M; Kimura K; Yoshida S
    Jpn J Cancer Res; 1985 Aug; 76(8):729-35. PubMed ID: 3930450
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Calculation of individual dosage regimen of cytosine arabinoside (ara-C) based on metabolite levels in leukemic cells.
    Riva-Lavieille C; Ressayre C; Barra Y; Carcassonne Y; Iliadis A
    Ther Drug Monit; 1994 Aug; 16(4):375-9. PubMed ID: 7974627
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.